Clinical Trials on Wild-type Transthyretin Amyloidosis

Total 373 results

Takeda

Completed

A Study to Investigate the Relationship Between Duration of Treatment and Response in Patients With Multiple Myeloma (MM) or Systemic AL Amyloidosis Treated in Real-life Practice (DOrianT)

Multiple Myeloma | Immunoglobulin Light-chain Amyloidosis

Spain
IRCCS Policlinico S. Matteo

Recruiting

A Registry of AL Amyloidosis (ReAL) (ReAL)

AL Amyloidosis

Italy
Prothena Biosciences Ltd.
Amyloidosis Research Consortium; Amyloidosis Support Groups; Amyloidosis Foundation and other collaborators

Completed

Quality of Life (QOL) Registry for Patients With AL Amyloidosis

AL Amyloidosis | Amyloidosis

United States
IRCCS Policlinico S. Matteo

Withdrawn

High Cut-off Hemodialysis in Patients With Advanced Cardiac AL Amyloidosis and End Stage Renal Disease (DIACAL)

Primary Amyloidosis of Light Chain Type

Italy
Prothena Biosciences Ltd.

Completed

The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis (PRONTO)

AL Amyloidosis

United States, Spain, Australia, Germany, United Kingdom, France, Greece, Israel, Italy, Austria
Mayo Clinic
National Cancer Institute (NCI)

Withdrawn

Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain Amyloidosis

Amyloidosis | Immunoglobulin Light Chain Deposition
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Terminated

First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD

Primary Systemic Amyloidosis | Light Chain Deposition Disease

United States, Canada
M.D. Anderson Cancer Center
Celgene

Terminated

Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis

Myeloma

United States
Alexion Pharmaceuticals, Inc.

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis

AL Amyloidosis

United States, Germany, Spain, Russian Federation, France, Korea, Republic of, Poland, Israel, Netherlands, Japan, Belgium, Greece, Switzerland, Australia, Austria, Brazil, Canada, China, Czechia, Italy, United Kingdom
Fondazione Toscana Gabriele Monasterio

Recruiting

18F-florbetaben PET-CT to Non-invasively Diagnose Cardiac AL Amyloidosis (PETAL)

Amyloid | Amyloid Cardiomyopathy

Italy
Novartis Pharmaceuticals

Completed

A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors (CCGM097X2101)

Solid Tumor With p53 Wild Type Status

France, Germany, Singapore, Switzerland, United States
Brigham and Women's Hospital
National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health... and other collaborators

Recruiting

Molecular Imaging of Primary Amyloid Cardiomyopathy (MICA)

Cardiomyopathy | Amyloidosis, Primary

United States
Sanofi

Recruiting

A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)

Relapsed/Refractory Multiple Myeloma | Amyloid Light-chain Amyloidosis

Italy, Australia, Hungary, United Kingdom, Czechia, Belgium, Spain
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease

Primary Systemic Amyloidosis | Light Chain Deposition Disease

United States
University of Pittsburgh

Completed

Return of Amyloid Imaging Results (RAISR Study) (RAISR)

Mild Cognitive Impairment
Boston Medical Center

Completed

Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis (MRD)

Multiple Myeloma

United States
Southwest Oncology Group
National Cancer Institute (NCI); Cancer and Leukemia Group B

Completed

S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis

Multiple Myeloma

United States
Alexion Pharmaceuticals, Inc.

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis

AL Amyloidosis

United States, Germany, Spain, United Kingdom, France, Korea, Republic of, Poland, Netherlands, Japan, Belgium, Greece, Australia, Austria, Brazil, Canada, China, Czechia, Israel, Italy, Russian Federation
Boston Medical Center

Completed

Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment in Patients With AL Amyloidosis (MRD)

Amyloidosis

United States
Nanjing University School of Medicine

Enrolling by invitation

Autologous Stem Cell Transplantation for Patients With AL Amyloidosis

AL Amyloidosis | Plasma Cell Dyscrasia

China
Memorial Sloan Kettering Cancer Center
Janssen Scientific Affairs, LLC

Active, not recruiting

Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis

Multiple Myeloma | AL Amyloidosis

United States
Vaishali Sanchorawala
Celgene Corporation

Completed

CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis

Multiple Myeloma

United States
Boston Medical Center

Completed

Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis

Multiple Myeloma

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

Nausea | Constipation | Diarrhea | Purpura | Lymphadenopathy | Gastrointestinal Hemorrhage | Hepatomegaly | Primary Systemic Amyloidosis | Amorphous, Eosinophilic, and Acellular Deposit | Early Satiety | Macroglossia | Recurrent Primary Amyloidosis | Refractory Primary Amyloidosis

United States
M.D. Anderson Cancer Center

Completed

Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden

Multiple Myeloma | Primary Amyloidosis

United States
Margarida Magalhaes-Silverman
National Cancer Institute (NCI)

Completed

Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Primary Systemic Amyloidosis | Light Chain Deposition Disease | Extramedullary Plasmacytoma | Isolated Plasmacytoma of Bone

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis

Multiple Myeloma | Plasma Cell Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis

Multiple Myeloma and Plasma Cell Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis

Multiple Myeloma and Plasma Cell Neoplasm

United States
Arbeitsgemeinschaft medikamentoese Tumortherapie
Amgen

Terminated

Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma

KRAS Wild Type | Resectable Type II Gastric Adenocarcinoma

Austria
Ohio State University Comprehensive Cancer Center

Recruiting

Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource (B-SCR-MM)

Multiple Myeloma | AL Amyloidosis | Monoclonal Gammopathy of Undetermined Significance | Plasma Cell Dyscrasias

United States
Tufts Medical Center
National Institute on Aging (NIA)

Completed

Screening to Improve Survival in AL Amyloidosis

Monoclonal Gammopathy of Undetermined Significance | Smoldering Multiple Myeloma

United States
Tufts Medical Center

Completed

A Diagnostic Screening Trial Seeking AL Amyloidosis Very Early (SAVE)

Plasma Cell Dyscrasia | Monoclonal Gammopathy

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis

Multiple Myeloma and Plasma Cell Neoplasm

United States
Herbert Irving Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis

Multiple Myeloma and Plasma Cell Neoplasm

United States
National Cancer Institute (NCI)

Completed

4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis

Multiple Myeloma and Plasma Cell Neoplasm

United States, Italy
Tufts Medical Center
National Cancer Institute (NCI)

Not yet recruiting

Screening for AL Amyloidosis in Smoldering Multiple Myeloma

Smoldering Multiple Myeloma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis

Multiple Myeloma and Plasma Cell Neoplasm

United States
First Affiliated Hospital Xi'an Jiaotong University

Enrolling by invitation

The Diagnostic Pattern and Prognosis of Multiple Myeloma Patients With Myocardial Amyloidosis Were Evaluated by NMR Based Metabolomics

Multiple Myeloma | Amyloidosis Cardiac

China
IRCCS Policlinico S. Matteo

Recruiting

Promoting Diagnosis and Management of AL in Italy (ProDigALIty) (ProDigALIty)

AL Amyloidosis | Monoclonal Gammopathy of Undetermined Significance | Smoldering Multiple Myeloma

Italy
Washington University School of Medicine
Karyopharm Therapeutics Inc

Recruiting

Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant

Multiple Myeloma | Myeloma-Associated Amyloidosis

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis

Amyloidosis | Plasma Cell Myeloma

United States
Memorial Sloan Kettering Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis

Amyloidosis | Light Chain Deposition Disease (LCDD or MIDD) | Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD) | Monoclonal Immunoglobulin Deposition Disease (MIDD)

United States
Peking University People's Hospital

Recruiting

Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients With MIDD

Monoclonal Gammopathy of Renal Significance

China
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Terminated

Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation

Multiple Myeloma and Plasma Cell Neoplasm | Drug/Agent Toxicity by Tissue/Organ

United States
Life Molecular Imaging SA

Completed

Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) Patients

Alzheimer Disease | Amyloid Beta-Protein

Australia
Neurozen Inc.
Chonnam National University Hospital; Chosun University Hospital

Completed

Evaluating the Efficacy of Artificial Intelligence-based Computer Aided Diagnosis Software That Assists in Determining Whether or Not to Conduct Amyloid PET for the Diagnosis of Alzheimer's Disease by Predicting Amyloid PET Positivity in Mild Cognitive Impairment Patients

Alzheimer Disease | Mild Cognitive Impairment

Korea, Republic of
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma

Plasma Cell Myeloma | Secondary Amyloidosis

United States
Barbara Ann Karmanos Cancer Institute

Completed

COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies

Multiple Myeloma | AL Amyloidosis | Chronic Lymphocytic Leukemia

United States
Hoffmann-La Roche

Terminated

A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma

Advanced BRAFV600 Wild-type Melanoma

United States, Korea, Republic of, Australia, Belgium, France, Russian Federation, Italy, Netherlands, Spain, United Kingdom, Brazil, Poland, Germany, Greece, Hungary

Clinical Trials on Wild-type Transthyretin Amyloidosis

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations